GE Healthcare launched KUBio today, an innovative off-the-shelf, modular factory, designed with the purpose of saving biopharmaceutical manufacturers time and money. KUBio's pre-made modules, which are assembled at a customer's chosen site to make a fully functional ready-to-run bio processing facility, are significantly faster to install than constructing a traditional factory. The modules are equipped with GE Healthcare's world-class technologies for the start-to-finish manufacture of biopharmaceuticals.
The global demand for biopharmaceuticals is increasingly driven by the global ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases. KUBio will help manufacturers to respond to local healthcare needs such as these and bring these potentially life-saving treatments to market more quickly. KUBio can help the vaccine industry to manufacture its vaccines more efficiently. The cost benefit of reducing production time could also potentially make global distribution of vaccines more financially manageable, thus helping to deliver vaccines to developing countries and emerging markets.
KUBio is a fully functional off-the-shelf bioprocessing facility specifically designed to meet cGMP requirements while optimizing manufacturing flexibility and productivity. The 1200m2 facility is pre-fabricated and delivered with a complete ready-to-use production line, based on GE Healthcare's Ready-to-ProcessTM flexible, single-use technologies. With a total planning, delivery and construction time of 14-18 months, compared to the traditional 24 -36 months, both time-to-market and level of capital investment are significantly reduced. GE Healthcare's start-to-finish technologies and services include Fast Trak training, PAA cell culture media, ReadyToProcess single use technologies, specialist purification media and Xcellerex biomanufacturing systems. KUBio aligns with GE's healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare.
Oliver Loeillot, General Manger of Enterprise Solutions, GE Healthcare said:
"KUBio is a totally new approach to the manufacture of biopharmaceuticals, bringing our customers a greatly simplified way to build their production capacity. With KUBio our customers will be able to cut months off the typical construction time, and greatly streamline the whole construction process. We're already seeing interest from a wide range of customers, from governments wanting to develop in-country manufacturing capability right through to pharmaceutical companies wanting to expand production capacity in new locations. KUBio is an industry game-changer that will help them do just that."
The introduction of KUBio expands GE Healthcare's broad offering of world-class tools, technologies and services for the biopharmaceutical manufacturing industry, allowing customers to benefit from a wide range of solutions that can be tailored to meet specific needs, from pilot to commercial scale.
To find out more about, please visit their website www.gehealthcare.com.
Please feel free to comment and tell us what you think below!
World Vaccine Congress Lyon is delighted to announce that GE Healthcare is sponsoring our 2012 congress. World Vaccine Congress Lyon is a key event for vaccinologists to meet with expert representatives from a wide variety of institutions and facilitates discussions that are vital for progression of the vaccine field.